As per attached Document

Results View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.2%Reaction day

₹139.95

prior close

₹141.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.4%-2.9% vs market

Pharmaceuticals peers, median of 159sector-0.7%-3.5% vs sector

On the reaction day the stock moved 2.9 pts less than Nifty Microcap 250 and 3.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.7

10m

-7.4

15m

-6.8

30m

-4.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.2-1.4-2.9-0.7-3.5

Next day

-5.0-0.9-4.0+0.0-5.0

-5.0-0.3-4.6+0.3-5.2

+3.3+0.8+2.5+1.1+2.1

+3.6+0.9+2.8+0.3+3.3

+7.1+2.5+4.7+1.1+6.1

+4.3+3.1+1.2+1.7+2.6

15d

+7.2+3.5+3.7+1.1+6.1

+7.1+8.0-0.9+2.6+4.6

+5.6+9.3-3.7+8.2-2.6

+42.9+14.0+28.9+8.1+34.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sanjivani Paranteral Limited reported FY26 total income of ₹697.56 million with EBITDA of ₹114 million (16.34% margin) and PAT of ₹66.94 million (9.60% margin). Revenue from operations stood at ₹686.66 million, with tablets segment growing approximately 7.5% YoY to ₹279.14 million and injectables contributing ₹346.15 million (53.45% of revenue). Exports contributed 78.50% of revenue at ₹508 million, with core markets (CIS, Middle East & Africa, Latin America) accounting for 77.01%. The company highlighted commencement of commercial production at its new IV Fluid Infusion Plant in Pune as a key milestone. Q4 FY26 showed revenue of ₹132.13 million with EBITDA margin of 15.74% and PAT margin of 3.97%.

Likely market impact

The company delivered healthy full-year profitability with 9.60% PAT margin and 16.34% EBITDA margin, supported by export-driven growth and new manufacturing capacity. The expansion into IV fluids positions the company for additional revenue streams in FY27.